Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies. Although both drugs avidly bind Bcl-2, Bcl-x(L), and Bcl-w in vitro, we find that Bcl-2 is the critical target in vi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mérino, Delphine, Khaw, Seong L., Glaser, Stefan P., Anderson, Daniel J., Belmont, Lisa D., Wong, Chihunt, Yue, Peng, Robati, Mikara, Phipson, Belinda, Fairlie, Walter D., Lee, Erinna F., Campbell, Kirsteen J., Vandenberg, Cassandra J., Cory, Suzanne, Roberts, Andrew W., Ludlam, Mary J. C., Huang, David C. S., Bouillet, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3382939/
https://ncbi.nlm.nih.gov/pubmed/22538851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-400929
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados